Corcept Therapeutics Inc.

CORT

Held by 4 specialist biotech funds

High Convergence

4 funds opened new positions. Next phase3 readout (Nab-paclitaxel 80 mg/m^2): Mar 2025. Short interest: 10.2% of float.

Medical - PharmaceuticalsCEO: Joseph K. BelanoffIPO: 2004Website ↗

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

Catalysts

Phase 2NegativeQ4 2005MifepristoneAlzheimer's DiseaseNCT00105105

Primary: effects on cognitionEnrollment:Target 160Sites: 21RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2006MifepristoneMajor Depressive Disorder, Psychotic DisordersNCT00130676

Primary: The change in a measure of psychosis (screening and on Days 0, 7, 14, 28, 42, and 56)Enrollment:257/257Sites: 23RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2006MifepristoneMajor Depressive DisorderNCT00146523

Primary: The change in a measure of psychosis (screening and on Days 0, 7, 14, 28, 42, and 56)Enrollment:247/247Sites: 19RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2006MifepristoneMajor Depressive Disorder, Psychotic DisordersNCT00128505

Primary: To evaluate the safety and tolerability of Corlux (mifepristone) for the treatment of recurrent psychotic symptoms with major depression with psychotic features (PMD) who previously participated in Corcept Therapeutics Protocol C-1073-09Enrollment:104/104Sites: 19NA, TREATMENT

Phase 3Q4 2006MifepristoneDepressive Disorder, MajorNCT00208156

Phase 3NegativeQ1 2007mifepristoneMajor Depressive Disorder, Psychotic DisordersNCT00128479

Primary: The change in a measure of psychosis (screen, Days 0, 7, 14, 28, 42, 56)Enrollment:443/443Sites: 44RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2007MifepristoneWeight-Gain PreventionNCT00455442

Primary: To determine the efficacy of mifepristone in the prevention of olanzapine-induced weight gain in healthy male volunteers.Enrollment:57/57Sites: 1RANDOMIZED, DOUBLE

Phase 3PositiveQ1 2011mifepristoneCushing's SyndromeNCT00569582

Primary: Improvement in Diabetes and/or Glucose Intolerance. (Baseline to Week 24)Enrollment:50/50Sites: 17NA, TREATMENT

Phase 3PositiveQ2 2012MifepristoneCushing's Disease, Cushing's SyndromeNCT01371565

Primary: Number of Participants With Adverse Events (6 months)Enrollment:4/4Sites: 5NA, TREATMENT

Phase 3PositiveQ3 2012mifepristoneCushing's SyndromeNCT00936741

Primary: Number of Participants With Adverse Events (Up to three years.)Enrollment:30/30Sites: 15NA, TREATMENT

Phase 3Q4 2016mifepristoneCushing's DiseaseNCT01925092

Primary: Adverse events (collected during the12 week study and 4 week follow-up period; up to 16 weeks total.)0Sites: 1NA, TREATMENT

Phase 2PositiveQ3 2018CORT125134Cushing's SyndromeNCT02804750

Primary: Percentage of Participants With One or More Adverse Events (Group 1: up to Week 16; Group 2: up to Week 20)Enrollment:35/35Sites: 25NON_RANDOMIZED, TREATMENT

Phase 2Q2 2020Relacorilant with nab-paclitaxelSolid TumorsNCT02762981

Primary: Number of Participants With Dose-limiting Toxicity (Up to completion of Cycle 1 (up to 28 days))Enrollment:85/85Sites: 4NA, TREATMENT

Phase 2NegativeQ2 2021MiricorilantNonalcoholic Steatohepatitis (NASH)NCT03823703

Primary: Relative Change From Baseline in Liver Fat Content Assessed by Magnetic Resonance Imaging-Proton Density Fat Fraction (Baseline and up to ~Day 95)Enrollment:12/12Sites: 15RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ4 2021ExicorilantMetastatic Castration-Resistant Prostate CancerNCT03437941

Phase 2Q3 2022MiricorlilantAntipsychotic-induced Weight Gain (AIWG)NCT04524403

Phase 3ApprovedQ2 2024RelacorilantCushing SyndromeNCT03697109

Phase 3PositiveQ3 2024RelacorilantHypercortisolismNCT04308590

Primary: Change in Average 24-hour SBP (Baseline and Week 22)Enrollment:137/137Sites: 45RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ1 2025Nab-paclitaxel 80 mg/m^2Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal NeoplasmsNCT05257408

Primary: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) (Up to 20 months)Enrollment:381/381Sites: 116RANDOMIZED, TREATMENT

Phase 2Q3 2026Relacorilant 150 mg once daily (QD)Ovarian Cancer, Fallopian Tube Cancer, Peritoneal NeoplasmsNCT06906341

Primary: Progression-Free Survival (PFS) (Date of first dose until PD or death, up to 18 months)Enrollment:Target 270Sites: 49NON_RANDOMIZED, TREATMENT

Phase 2Sep 15, 2026Mifepristone 1200 mg dailyTreatment-resistant PTSDNCT06689254

Primary: Improvement of PTSD symptoms (4 weeks after the start of the intervention (T2))Enrollment:Target 60Sites: 1RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q3 2026Miricorilant (Cohort A)Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)NCT06108219

Phase 2Q3 2026Nenocorilant 200 mgNeoplasmsNCT07276373

Primary: Number of Patients With 1 or More Adverse Event (From first dose of study treatment up to 28 days after final dose, assessed up to 9 months)Enrollment:Target 50Sites: 5NON_RANDOMIZED, TREATMENT

Phase 2Q4 2026Dazucorilant 300 mgAmyotrophic Lateral SclerosisNCT05407324

Primary: Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score. (Baseline to Week 24)Enrollment:Target 279Sites: 35RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2026relacorilantCushing SyndromeNCT03604198

Primary: Long-term safety of relacorilant (36 months)Enrollment:125/125Sites: 48NA, TREATMENT

Phase 2Q3 2027RelacorilantAdenocarcinoma, Carcinoma, Pancreatic DuctalNCT07259317

Phase 2Q4 2027EnzalutamideMetastatic Breast CancerNCT06099769

Recent News & Research

PubMed

Alkaline Phosphatase and Prostate-specific Antigen Response in Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide Alone or in Combination with Radium-223: Ad Hoc Analysis of the PEACE-3 Consortium Trial.

# Summary for CORT Investors I cannot provide the analysis you requested because this research article concerns enzalutamide and radium-223 for prostate cancer—neither of which is directly relevant to Corcept Therapeutics' core business of glucocorticoid receptor (GR) antagonists, primarily mifepristone (Korlym) for Cushing's syndrome. **Why this matters for your tracking:** Unless Corcept has announced pipeline expansion into oncology or prostate cancer indications, this PEACE-3 Consortium data has no material bearing on CORT's clinical or commercial trajectory. I'd recommend focusing your research on Corcept-specific trials, particularly any updates on mifepristone's regulatory status or new indication development.

Aug 28, 2026

PubMed

Relacorilant in Combination With Nab-Paclitaxel for the Treatment of Adults With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

# Investment Summary: Relacorilant + Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer This study evaluates relacorilant (Corcept's selective glucocorticoid receptor antagonist) combined with standard-of-care nab-paclitaxel in platinum-resistant epithelial ovarian cancer, a high-mortality indication with limited treatment options and recurring resistance mechanisms. Positive efficacy/safety data from this combination would expand relacorilant's addressable market beyond its approved indication (Cushing's syndrome) and validate the glucocorticoid receptor pathway as therapeutically relevant in solid tumors where high cortisol contributes to chemotherapy resistance and immunosuppression. Commercial success would depend on regulatory approval, payer reimbursement for the combination regimen, and competitive positioning against other emerging platinum-resistant ovarian cancer treatments.

Aug 27, 2026

PubMed

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

# ROSELLA Trial Summary for CORT Investors The ROSELLA phase 3 trial demonstrates that relacorilant (Corcept's selective glucocorticoid receptor antagonist) combined with nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer patients, potentially establishing a new standard of care in a significant unmet need. This positive OS data—the primary endpoint—supports relacorilant's commercial viability beyond its established indication (adrenocorticotropic hormone-independent Cushing's syndrome) and validates the immunomodulatory mechanism in solid tumors. The result substantiates Corcept's pipeline expansion strategy and could enable label expansion into platinum-resistant ovarian cancer, opening a larger addressable market with meaningful clinical differentiation.

Apr 18, 2026

PubMed

Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study.

# GRACE Trial Summary for CORT Investors **Clinical Findings:** The GRACE trial demonstrates that relacorilant (CORT's lead candidate) met its primary endpoint, showing statistically significant efficacy in reducing cortisol levels in Cushing's syndrome patients during the randomized-withdrawal phase, with a favorable safety profile supporting differentiation from existing therapies like mifepristone. **Commercial Implications:** This Phase 3 data strengthens CORT's competitive position in the rare Cushing's syndrome market, potentially supporting FDA approval and providing clinical evidence for market adoption; however, investors should assess the magnitude of benefit versus Korlym (mifepristone) and the addressable patient population to evaluate peak sales potential and timing to commercialization. **Why It Matters:** Cushing's syndrome is a high-unmet-need, ultra-rare indication with limited treatment options

Apr 1, 2026

PubMed

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.

# Investment Summary: Not Applicable to CORT **This research is not relevant to Corcept Therapeutics.** The study examines enzalutamide (an androgen receptor antagonist developed by Astellas/Medivation) in prostate cancer patients, which is outside CORT's therapeutic focus. CORT's pipeline centers on glucocorticoid receptor modulators for Cushing's syndrome and other endocrine/metabolic disorders, with no overlap in indication, mechanism, or competitive positioning with prostate cancer therapeutics. **Recommendation:** Flag and exclude from CORT-specific tracking.

Mar 27, 2026

Corcept Therapeutics Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research